Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Voyager Therapeutics, Inc. (VYGR)
USD3.18
+0.02 (+0.47%)
US NASDAQ Healthcare Biotechnology
Address
75 Sidney Street 2139
Lexington, MA, US
Lexington, MA, US
CEO
Alfred W. Sandrock Jr.
Website
voyagertherapeutics.com
IPO
2015-11-11
CIK 1640266 ISIN US92915B1061
Description
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.18
+0.02 (+0.47%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
572.4K
Beta
1.25
Float Shares
50.30M
Free Float %
83.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.73% | +0.24% | +10.16% | +20.47% | -3.06% | +4.83% | +22.99% | -60.54% | -7.83% | -65.14% | -76.79% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (21 ratings, all time)
Buy
Price Targets & DCF
Current price
3.18
Low
8.00
+152.0%
Consensus
14.40
+353.5%
Median
18.00
+466.9%
High
18.00
+466.9%
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 11 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 6 |
14.33
+351.3%
|
Quality scores
Altman Z-Score
-0.75
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-49.5% Q1'26: -59.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-80.5% Q1'26: +11.3% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-394.5% Q1'26: -1,289.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-326.6% Q1'26: -1,167.4% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-364.9% Q1'26: -181.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1.8% ★ Q1'26: +2.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.29× Q1'26: -0.29× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 8 Rev. Ana. 7 EPS Ana. |
Dec 2027 8 Rev. Ana. 9 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
17.33M
est: 14.00M (+23.8%)
|
14.22M
est: 16.14M (-11.9%)
|
10.14M
est: 8.57M (+18.3%)
|
7.62M
est: 8.10M (-5.9%)
|
104.39M
est: 84.07M (+24.2%)
|
171.13M
est: 180.41M (-5.1%)
|
37.42M
est: 13.62M (+174.7%)
|
40.91M
est: 46.16M (-11.4%)
|
250.01M
est: 143.77M (+73.9%)
|
80.00M
est: 90.30M (-11.4%)
|
40.37M
est: 35.53M (+13.6%)
|
49.49M
25.22M – 76.03M
+39.3% YoY
|
60.78M
51.54M – 85.04M
+22.8% YoY
|
69.26M
66.18M – 72.34M
+14.0% YoY
|
96.41M
51.54M – 163.40M
+39.2% YoY
|
95.06M
50.82M – 161.12M
-1.4% YoY
|
| EBITDA |
-19.65M
est: -6.34M (-210.2%)
|
-40.69M
est: -7.30M (-457.1%)
|
-70.27M
est: -3.88M (-1,711.6%)
|
-88.98M
est: -131.76M (+32.5%)
|
-48.91M
est: -38.05M (-28.5%)
|
31.20M
est: -81.65M (+138.2%)
|
-68.45M
est: -6.16M (-1,010.4%)
|
-39.65M
est: -62.11M (+36.2%)
|
126.46M
est: -99.07M (+227.6%)
|
-78.56M
est: -62.22M (-26.3%)
|
-127.78M
est: -24.49M (-421.9%)
|
-34.11M
-52.39M – -17.38M
-39.3% YoY
|
-41.88M
-58.60M – -35.51M
-22.8% YoY
|
-47.72M
-49.84M – -45.60M
-14.0% YoY
|
-66.43M
-112.59M – -35.51M
-39.2% YoY
|
-65.50M
-111.02M – -35.02M
+1.4% YoY
|
| EBIT |
-20.25M
est: -6.59M (-207.6%)
|
-41.30M
est: -7.59M (-444.1%)
|
-71.86M
est: -4.03M (-1,682.6%)
|
-91.10M
est: -140.06M (+35.0%)
|
-51.68M
est: -39.55M (-30.7%)
|
27.38M
est: -84.86M (+132.3%)
|
-73.62M
est: -6.41M (-1,049.0%)
|
-45.84M
est: -78.30M (+41.5%)
|
122.01M
est: -100.98M (+220.8%)
|
-83.29M
est: -63.42M (-31.3%)
|
-131.84M
est: -24.96M (-428.2%)
|
-34.76M
-53.40M – -17.72M
-39.3% YoY
|
-42.69M
-59.73M – -36.20M
-22.8% YoY
|
-48.65M
-50.81M – -46.49M
-14.0% YoY
|
-67.72M
-114.77M – -36.20M
-39.2% YoY
|
-66.77M
-113.17M – -35.69M
+1.4% YoY
|
| Net Income |
-29.67M
est: -348.70M (+91.5%)
|
-40.19M
est: -81.39M (+50.6%)
|
-70.70M
est: -163.58M (+56.8%)
|
-88.29M
est: -134.36M (+34.3%)
|
-43.60M
est: -90.98M (+52.1%)
|
36.74M
est: 1.01B (-96.4%)
|
-71.20M
est: -135.15M (+47.3%)
|
-46.41M
est: 95.83M (-148.4%)
|
132.33M
est: 9.02M (+1,366.6%)
|
-65.00M
est: -50.96M (-27.6%)
|
-119.72M
est: -119.72M (+0.0%)
|
-116.46M
-148.90M – -57.00M
+2.7% YoY
|
-122.43M
-132.33M – -65.24M
-5.1% YoY
|
-134.62M
-175.64M – 3.63M
-10.0% YoY
|
-71.69M
-136.44M – -28.31M
+46.7% YoY
|
-61.76M
-117.56M – -24.39M
+13.8% YoY
|
| SGA |
9.91M
est: 7.14M (+38.8%)
|
13.27M
est: 8.23M (+61.3%)
|
19.74M
est: 4.37M (+351.7%)
|
33.81M
est: 4.13M (+718.8%)
|
36.34M
est: 42.87M (-15.2%)
|
34.99M
est: 138.43M (-74.7%)
|
37.25M
est: 6.95M (+436.3%)
|
30.98M
est: 41.44M (-25.2%)
|
35.82M
est: 94.17M (-62.0%)
|
35.92M
est: 59.14M (-39.3%)
|
37.54M
est: 23.27M (+61.3%)
|
32.42M
16.52M – 49.80M
+39.3% YoY
|
39.81M
33.76M – 55.70M
+22.8% YoY
|
45.36M
43.35M – 47.38M
+14.0% YoY
|
63.15M
33.76M – 107.03M
+39.2% YoY
|
62.27M
33.28M – 105.53M
-1.4% YoY
|
| EPS |
-7.08
est: -6.05 (-17.1%)
|
-1.59
est: -1.41 (-12.7%)
|
-2.64
est: -2.84 (+6.9%)
|
-2.75
est: -2.69 (-2.4%)
|
-1.14
est: -1.58 (+27.7%)
|
0.99
est: 0.85 (+17.0%)
|
-1.75
est: -2.34 (+25.3%)
|
-1.21
est: -1.16 (-4.7%)
|
3.08
est: 0.18 (+1,629.9%)
|
-1.13
est: -0.92 (-22.3%)
|
-2.04
est: -2.09 (+2.4%)
|
-1.71
-2.54 – -0.97
+18.0% YoY
|
-1.59
-2.25 – -1.11
+7.0% YoY
|
-1.57
-2.99 – 0.06
+1.6% YoY
|
-1.22
-2.32 – -0.48
+22.1% YoY
|
-1.05
-2.00 – -0.42
+13.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-143.23M
OE per share TTM
-2.43
Owner's Yield
-58.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
43.6%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
36
Total invested
7.10M
Insider transactions (90d)
0
Beneficial owners (>5%)
26
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 4.28M | 11.00% | — | 4.28M | — | 4.28M | IA, OO | Delaware | 2022-04-26 | ↗ |
| 2 | Oleg Nodelman | 4.28M | 11.00% | — | 4.28M | — | 4.28M | HC, IN | Delaware | 2022-04-26 | ↗ |
| 3 | EcoR1 Capital Fund Qualified, L.P. | 3.98M | 11.00% | — | 3.98M | — | 3.98M | PN | Delaware | 2022-04-26 | ↗ |
| 4 | FMR LLC | 3.90M | 14.57% | — | — | 3.90M | — | HC | Delaware | 2015-12-10 | ↗ |
| 5 | Armistice Capital, LLC | 3.40M | 8.80% | — | 3.40M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 6 | Steven Boyd | 3.40M | 8.80% | — | 3.40M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 7 | (1) BlackRock, Inc. | 2.63M | 6.00% | 2.62M | — | 2.63M | — | HC | Delaware | 2024-01-29 | ↗ |
| 8 | 10. | 2.48M | 9.30% | — | — | — | 2.48M | CO | Republic France | 2016-02-12 | ↗ |
| 9 | The Vanguard Group - 23-1945930 | 2.07M | 5.46% | — | 4.8K | 2.06M | 14.3K | IA | Pennsylvania For | 2022-02-10 | ↗ |
| 10 | Armistice Capital Master Fund Ltd. | 2.00M | 5.40% | — | 2.00M | — | 2.00M | CO | Delaware | 2020-03-05 | ↗ |
| 11 | UBS Group AG directly and on behalf of certain subsidiaries | 1.99M | 6.10% | — | 1.99M | — | 1.99M | BK | Switzerland | 2019-02-15 | ↗ |
| 12 | 1,786,341 | 1.79M | 5.60% | — | 1.79M | — | 1.79M | HC, CO | Switzerland | 2018-01-10 | ↗ |
| 13 | 2. | 1.79M | 5.60% | — | 1.79M | — | 1.79M | CO | Switzerland | 2018-01-10 | ↗ |
| 14 | Wellington Group Holdings LLP | 1.47M | 5.50% | — | 1.33M | — | — | HC | Delaware | 2016-02-11 | ↗ |
| 15 | Wellington Investment Advisors Holdings LLP | 1.47M | 5.50% | — | 1.33M | — | — | HC | Delaware | 2016-02-11 | ↗ |
| 16 | Wellington Management Group LLP | 1.47M | 5.50% | — | 1.33M | — | — | HC | Massachusetts | 2016-02-11 | ↗ |
| 17 | Wellington Management Company LLP | 1.43M | 5.36% | — | 1.33M | — | — | IA | Delaware | 2016-02-11 | ↗ |
| 18 | Deerfield Management Company, L.P. | 235.3K | 0.88% | — | 235.3K | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 19 | James E. Flynn | 235.3K | 0.88% | — | 235.3K | — | — | IN | United States | 2016-02-16 | ↗ |
| 20 | Deerfield Mgmt III, L.P. | 117.6K | 0.44% | — | 117.6K | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 21 | Deerfield Mgmt, L.P. | 117.6K | 0.44% | — | 117.6K | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 22 | Deerfield Private Design Fund III, L.P. | 117.6K | 0.44% | — | 117.6K | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 23 | Deerfield Special Situations Fund, L.P. | 117.6K | 0.44% | — | 117.6K | — | — | PN | Delaware | 2016-02-16 | ↗ |
| 24 | Brian D. Grossman | 6.00 | 6.00% | — | 1.95M | — | 1.95M | IN | Delaware | 2019-04-01 | ↗ |
| 25 | Brookside Capital Partners Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
| 26 | Brookside Capital Trading Fund, L.P. | — | 0.00% | — | — | — | — | PN | Delaware | 2018-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
36
-90 vs prev Q
New positions
7
Closed positions
93
Increased
19
Reduced
8
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BLACKROCK, INC. | 5.62M +11.1K (+0.2%) | 22.08M -4.1M (-15.7%) | 9.55% -0.003 pp | 0.00% 0.000 pp | USD5.67 -30.7% | 6 qtrs — |
| 2 | ECOR1 CAPITAL, LLC | 4.00M +3.3M (+497.2%) | 15.73M +12.6M (+402.5%) | 6.81% +5.665 pp | 0.71% +0.564 pp | USD3.88 +1.3% | 18 qtrs — |
| 3 | ARMISTICE CAPITAL, LLC | 4.00M -200.0K (-4.8%) | 15.72M -3.9M (-19.9%) | 6.80% -0.357 pp | 0.19% -0.104 pp | USD7.43 -47.1% | 31 qtrs — |
| 4 | VANGUARD GROUP INC | 3.27M +16.4K (+0.5%) | 12.84M -2.3M (-15.4%) | 5.56% +0.015 pp | 0.00% +0.000 pp | USD12.43 -68.4% | 41 qtrs — |
| 5 | MILLENNIUM MANAGEMENT LLC | 1.88M -411.9K (-18.0%) | 7.39M -3.3M (-31.0%) | 3.20% -0.710 pp | 0.00% -0.002 pp | USD4.17 -5.8% | 19 qtrs — |
| 6 | VESTAL POINT CAPITAL, LP | 1.48M +— (+0.0%) | 5.80M -1.1M (-15.8%) | 2.51% -0.006 pp | 0.20% -0.114 pp | USD6.87 -42.8% | 8 qtrs — |
| 7 | ERSTE ASSET MANAGEMENT GMBH | 1.20M +78.3K (+7.0%) | 4.72M -542.4K (-10.3%) | 2.03% +0.129 pp | 0.04% -0.011 pp | USD6.85 -42.6% | 29 qtrs — |
| 8 | OPALEYE MANAGEMENT INC. | 1.20M +1.2M (+100.0%) | 4.70M +4.7M (+100.0%) | 2.04% +2.035 pp | 0.62% +0.621 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.14M -13.4K (-1.2%) | 4.46M -902.9K (-16.8%) | 1.93% -0.027 pp | 0.00% 0.000 pp | USD10.56 -62.8% | 41 qtrs — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 1.08M -198.7K (-15.5%) | 4.26M -1.7M (-28.9%) | 1.84% -0.343 pp | 0.00% 0.000 pp | USD7.06 -44.3% | 25 qtrs — |
| 11 | STATE STREET CORP | 936.3K +10.9K (+1.2%) | 3.68M -641.9K (-14.9%) | 1.59% +0.015 pp | 0.00% +0.000 pp | USD10.80 -63.6% | 41 qtrs — |
| 12 | CITADEL ADVISORS LLC | 556.6K +158.4K (+39.8%) | 2.19M +327.9K (+17.6%) | 0.95% +0.268 pp | 0.00% +0.000 pp | USD3.97 -1.0% | 34 qtrs — |
| 13 | MORGAN STANLEY | 544.1K -55.6K (-9.3%) | 2.14M -662.2K (-23.6%) | 0.93% -0.097 pp | 0.00% +0.000 pp | USD6.72 -41.5% | 41 qtrs — |
| 14 | PRICE T ROWE ASSOCIATES INC /MD/ | 521.7K -60.0K (-10.3%) | 2.05M -666.0K (-24.5%) | 0.89% -0.104 pp | 0.00% 0.000 pp | USD7.59 -48.2% | 20 qtrs — |
| 15 | NORTHERN TRUST CORP | 368.5K -26.2K (-6.6%) | 1.45M -395.1K (-21.4%) | 0.63% -0.046 pp | 0.00% 0.000 pp | USD11.25 -65.1% | 41 qtrs — |
| 16 | SPHERA FUNDS MANAGEMENT LTD. | 339.8K +140.0K (+70.1%) | 1.34M +402.4K (+43.1%) | 0.58% +0.237 pp | 0.26% +0.061 pp | USD4.37 -10.1% | 2 qtrs — |
| 17 | FIDUCIARY TRUST CO | 334.4K +— (+0.0%) | 1.31M -247.5K (-15.8%) | 0.57% -0.001 pp | 0.01% -0.003 pp | USD8.65 -54.6% | 38 qtrs — |
| 18 | JPMORGAN CHASE & CO | 326.2K +108.8K (+50.1%) | 1.28M +266.8K (+26.3%) | 0.55% +0.184 pp | 0.00% +0.000 pp | USD6.51 -39.6% | 41 qtrs — |
| 19 | GOLDMAN SACHS GROUP INC | 303.1K +5.6K (+1.9%) | 1.19M -198.4K (-14.3%) | 0.52% +0.008 pp | 0.00% +0.000 pp | USD7.62 -48.4% | 41 qtrs — |
| 20 | RENAISSANCE TECHNOLOGIES LLC | 296.5K +34.0K (+13.0%) | 1.17M -60.6K (-4.9%) | 0.50% +0.057 pp | 0.00% +0.000 pp | USD4.13 -4.8% | 35 qtrs — |
| 21 | UBS GROUP AG | 268.8K -204.3K (-43.2%) | 1.06M -1.2M (-52.2%) | 0.46% -0.349 pp | 0.00% 0.000 pp | USD4.57 -14.0% | 41 qtrs — |
| 22 | TWO SIGMA INVESTMENTS, LP | 222.7K +82.0K (+58.3%) | 875.3K +218.1K (+33.2%) | 0.38% +0.139 pp | 0.00% +0.000 pp | USD4.40 -10.7% | 2 qtrs — |
| 23 | ALTSHULER SHAHAM LTD | 203.7K +203.7K (+100.0%) | 800.7K +800.7K (+100.0%) | 0.35% +0.347 pp | 0.01% +0.012 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 24 | BANK OF AMERICA CORP /DE/ | 176.1K -251.3K (-58.8%) | 692.1K -1.3M (-65.3%) | 0.30% -0.429 pp | 0.00% 0.000 pp | USD3.54 +11.0% | 41 qtrs — |
| 25 | BARCLAYS PLC | 162.1K +57.7K (+55.2%) | 637.1K +26.0K (+4.3%) | 0.28% +0.098 pp | 0.00% +0.000 pp | USD5.09 -22.8% | 14 qtrs — |
| 26 | AQR CAPITAL MANAGEMENT LLC | 160.0K -16.2K (-9.2%) | 628.9K -194.0K (-23.6%) | 0.27% -0.028 pp | 0.00% 0.000 pp | USD5.28 -25.6% | 10 qtrs — |
| 27 | AMERICAN CENTURY COMPANIES INC | 150.4K +3.9K (+2.7%) | 591.1K -92.9K (-13.6%) | 0.26% +0.006 pp | 0.00% 0.000 pp | USD7.88 -50.1% | 11 qtrs — |
| 28 | JANE STREET GROUP, LLC | 149.7K -10.7K (-6.7%) | 588.5K -161.0K (-21.5%) | 0.25% -0.019 pp | 0.00% +0.000 pp | USD4.88 -19.5% | 8 qtrs — |
| 29 | FMR LLC | 141.7K +23.0K (+19.4%) | 557.0K +2.7K (+0.5%) | 0.24% +0.039 pp | 0.00% +0.000 pp | USD6.06 -35.1% | 41 qtrs — |
| 30 | BANK OF NEW YORK MELLON CORP | 139.3K -54.1K (-28.0%) | 547.6K -355.7K (-39.4%) | 0.24% -0.093 pp | 0.00% 0.000 pp | USD9.26 -57.6% | 41 qtrs — |
| 31 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 137.9K -4.0 (0.0%) | 541.9K -102.1K (-15.8%) | 0.23% -0.001 pp | 0.00% +0.000 pp | USD9.59 -59.0% | 16 qtrs — |
| 32 | WELLS FARGO & COMPANY/MN | 132.7K +28.0K (+26.7%) | 521.4K +32.4K (+6.6%) | 0.23% +0.047 pp | 0.00% +0.000 pp | USD6.82 -42.4% | 41 qtrs — |
| 33 | INVESCO LTD. | 116.0K +25.5K (+28.2%) | 455.9K +33.3K (+7.9%) | 0.20% +0.043 pp | 0.00% +0.000 pp | USD4.78 -17.8% | 11 qtrs — |
| 34 | CAPTRUST FINANCIAL ADVISORS | 103.6K +82.0 (+0.1%) | 407.3K -76.3K (-15.8%) | 0.18% 0.000 pp | 0.00% 0.000 pp | USD10.63 -63.0% | 11 qtrs — |
| 35 | PATRIOT FINANCIAL GROUP INSURANCE AGENCY, LLC | 102.7K -14.6K (-12.4%) | 403.7K -144.0K (-26.3%) | 0.17% -0.025 pp | 0.05% -0.022 pp | USD7.31 -46.2% | 7 qtrs — |
| 36 | ACADIAN ASSET MANAGEMENT LLC | 100.5K -50.4K (-33.4%) | 394.0K -308.0K (-43.9%) | 0.17% -0.086 pp | 0.00% -0.001 pp | USD3.67 +7.1% | 32 qtrs — |
| 37 | POINT72 ASSET MANAGEMENT, L.P. | 95.4K +95.4K (+100.0%) | 374.7K +374.7K (+100.0%) | 0.16% +0.162 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 38 | PRIVIUM FUND MANAGEMENT B.V. | 95.0K +50.0K (+111.1%) | 373.4K +163.2K (+77.7%) | 0.16% +0.085 pp | 0.07% +0.031 pp | USD3.93 +0.0% | 4 qtrs — |
| 39 | NUVEEN, LLC | 93.2K +— (+0.0%) | 366.1K -68.9K (-15.8%) | 0.16% 0.000 pp | 0.00% +0.000 pp | USD3.38 +16.3% | 4 qtrs — |
| 40 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 91.7K -2.4K (-2.6%) | 361.3K -78.5K (-17.9%) | 0.16% -0.005 pp | 0.00% 0.000 pp | USD6.54 -39.9% | 15 qtrs — |
| 41 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 87.5K +— (+0.0%) | 343.7K -64.7K (-15.8%) | 0.15% 0.000 pp | 0.01% -0.002 pp | USD4.95 -20.6% | 9 qtrs — |
| 42 | OMERS ADMINISTRATION CORP | 83.0K +11.1K (+15.4%) | 326.2K -9.8K (-2.9%) | 0.14% +0.019 pp | 0.00% 0.000 pp | USD7.34 -46.5% | 7 qtrs — |
| 43 | BIRCHVIEW CAPITAL, LP | 74.9K -60.0K (-44.5%) | 294.4K -335.6K (-53.3%) | 0.13% -0.103 pp | 0.17% -0.303 pp | USD4.67 -15.8% | 2 qtrs — |
| 44 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 65.2K +10.0K (+18.0%) | 256.2K -1.7K (-0.7%) | 0.11% +0.017 pp | 0.00% +0.000 pp | USD5.32 -26.1% | 29 qtrs — |
| 45 | BNP PARIBAS ARBITRAGE, SNC | 64.2K +21.9K (+51.6%) | 252.3K +54.6K (+27.6%) | 0.11% +0.037 pp | 0.00% +0.000 pp | USD4.37 -10.1% | 41 qtrs — |
| 46 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 61.8K +5.4K (+9.6%) | 249.0K -14.2K (-5.4%) | 0.11% +0.009 pp | 0.00% +0.000 pp | USD5.88 -33.2% | 10 qtrs — |
| 47 | TWO SIGMA ADVISERS, LP | 62.6K +4.0K (+6.8%) | 246.0K -27.6K (-10.1%) | 0.11% +0.007 pp | 0.00% 0.000 pp | USD4.62 -14.9% | 2 qtrs — |
| 48 | RHUMBLINE ADVISERS | 58.9K -11.1K (-15.8%) | 231.5K -95.3K (-29.2%) | 0.10% -0.019 pp | 0.00% 0.000 pp | USD9.73 -59.6% | 11 qtrs — |
| 49 | ALLIANCEBERNSTEIN L.P. | 58.8K +— (+0.0%) | 231.2K -43.5K (-15.8%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD6.91 -43.1% | 11 qtrs — |
| 50 | WALLEYE CAPITAL LLC | 55.8K +55.8K (+100.0%) | 219.5K +219.5K (+100.0%) | 0.10% +0.095 pp | 0.00% +0.001 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 51 | IKARIAN CAPITAL, LLC | 53.1K -2.7K (-4.8%) | 208.5K -51.9K (-19.9%) | 0.09% -0.005 pp | 0.02% -0.010 pp | USD11.38 -65.5% | 11 qtrs — |
| 52 | HSBC HOLDINGS PLC | 52.6K -95.4K (-64.4%) | 206.3K -468.8K (-69.4%) | 0.09% -0.163 pp | 0.00% 0.000 pp | USD4.10 -4.1% | 9 qtrs — |
| 53 | TD ASSET MANAGEMENT INC | 44.4K +— (+0.0%) | 174.3K -32.8K (-15.8%) | 0.08% 0.000 pp | 0.00% +0.000 pp | USD7.91 -50.3% | 15 qtrs — |
| 54 | PALUMBO WEALTH MANAGEMENT LLC | 38.5K +38.5K (+100.0%) | 151.3K +151.3K (+100.0%) | 0.07% +0.066 pp | 0.04% +0.037 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 55 | MAREX GROUP PLC | 38.3K +— (+0.0%) | 150.6K -28.4K (-15.8%) | 0.07% 0.000 pp | 0.00% 0.000 pp | USD3.11 +26.4% | 3 qtrs — |
| 56 | STRS OHIO | 38.0K -12.7K (-25.0%) | 149.3K -87.4K (-36.9%) | 0.06% -0.022 pp | 0.00% 0.000 pp | USD8.67 -54.7% | 11 qtrs — |
| 57 | ETHIC INC. | 36.7K -1.6K (-4.2%) | 144.4K -34.7K (-19.4%) | 0.06% -0.003 pp | 0.00% -0.001 pp | USD3.11 +26.4% | 3 qtrs — |
| 58 | JUMP FINANCIAL, LLC | 36.3K +36.3K (+100.0%) | 142.7K +142.7K (+100.0%) | 0.06% +0.062 pp | 0.00% +0.002 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 59 | ADAR1 CAPITAL MANAGEMENT, LLC | 35.0K +— (+0.0%) | 137.6K -25.9K (-15.8%) | 0.06% 0.000 pp | 0.01% -0.005 pp | USD5.94 -33.8% | 9 qtrs — |
| 60 | DEUTSCHE BANK AG\ | 31.7K +31.7K (+100.0%) | 124.5K +124.5K (+100.0%) | 0.05% +0.054 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 15 qtrs — |
| 61 | QUANTINNO CAPITAL MANAGEMENT LP | 31.3K +31.3K (+100.0%) | 123.0K +123.0K (+100.0%) | 0.05% +0.053 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 62 | QUADRATURE CAPITAL LTD | 30.4K +30.4K (+100.0%) | 119.6K +119.6K (+100.0%) | 0.05% +0.052 pp | 0.00% +0.001 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 63 | RAYMOND JAMES FINANCIAL INC | 25.1K -3.5K (-12.3%) | 98.5K -34.9K (-26.2%) | 0.04% -0.006 pp | 0.00% +0.000 pp | USD5.67 -30.7% | 5 qtrs — |
| 64 | VESTCOR INC | 22.9K +— (+0.0%) | 90.0K -17.0K (-15.9%) | 0.04% 0.000 pp | 0.00% -0.001 pp | USD11.45 -65.7% | 11 qtrs — |
| 65 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 21.6K -735.0 (-3.3%) | 84.8K -19.4K (-18.6%) | 0.04% -0.001 pp | 0.00% +0.000 pp | USD7.41 -47.0% | 7 qtrs — |
| 66 | HUNTER PERKINS CAPITAL MANAGEMENT, LLC | 21.0K -32.9K (-61.1%) | 82.0K -169.0K (-67.3%) | 0.04% -0.056 pp | 0.02% -0.037 pp | USD10.39 -62.2% | 8 qtrs — |
| 67 | INTECH INVESTMENT MANAGEMENT LLC | 19.0K -2.3K (-10.7%) | 74.6K -24.7K (-24.8%) | 0.03% -0.004 pp | 0.00% 0.000 pp | USD4.96 -20.8% | 6 qtrs — |
| 68 | ASSENAGON ASSET MANAGEMENT S.A. | 16.4K +16.4K (+100.0%) | 64.4K +64.4K (+100.0%) | 0.03% +0.028 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 69 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | 15.7K +15.7K (+42,410.8%) | 61.8K +61.6K (+35,631.2%) | 0.03% +0.027 pp | 0.02% +0.015 pp | USD3.93 +0.0% | 4 qtrs — |
| 70 | HRT FINANCIAL LP | 15.5K -21.8K (-58.5%) | 60.0K -114.0K (-65.5%) | 0.03% -0.037 pp | 0.00% -0.001 pp | USD4.67 -15.8% | 2 qtrs — |
| 71 | METLIFE INVESTMENT MANAGEMENT, LLC | 15.2K -11.5K (-43.2%) | 59.8K -65.2K (-52.2%) | 0.03% -0.020 pp | 0.00% 0.000 pp | USD8.66 -54.6% | 11 qtrs — |
| 72 | XTX TOPCO LTD | 14.4K -8.6K (-37.3%) | 56.7K -50.8K (-47.3%) | 0.02% -0.015 pp | 0.00% -0.004 pp | USD4.67 -15.8% | 5 qtrs — |
| 73 | POLICE & FIREMEN'S RETIREMENT SYSTEM OF NEW JERSEY | 14.2K +— (+0.0%) | 55.8K -10.5K (-15.8%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD5.36 -26.7% | 5 qtrs — |
| 74 | CETERA INVESTMENT ADVISERS | 14.2K +— (+0.0%) | 55.7K -10.5K (-15.8%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD4.67 -15.8% | 2 qtrs — |
| 75 | NEW YORK STATE COMMON RETIREMENT FUND | 12.7K +— (+0.0%) | 50.0K -9.4K (-15.8%) | 0.02% 0.000 pp | 0.00% +0.000 pp | USD11.33 -65.3% | 11 qtrs — |
| 76 | COLDSTREAM CAPITAL MANAGEMENT INC | 11.7K -26.0 (-0.2%) | 46.2K -8.8K (-16.0%) | 0.02% 0.000 pp | 0.00% 0.000 pp | USD4.67 -15.8% | 2 qtrs — |
| 77 | BANK OF MONTREAL /CAN/ | 11.5K +— (+0.0%) | 45.2K -8.5K (-15.8%) | 0.02% +0.000 pp | 0.00% +0.000 pp | USD3.11 +26.4% | 3 qtrs — |
| 78 | CIBC ASSET MANAGEMENT INC | 11.3K +11.3K (+100.0%) | 44.5K +44.5K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 79 | COMMONWEALTH EQUITY SERVICES, LLC | 11.3K -5.2K (-31.7%) | 44.2K -32.8K (-42.6%) | 0.02% -0.009 pp | 0.00% +0.000 pp | USD9.70 -59.5% | 8 qtrs — |
| 80 | PROSHARE ADVISORS LLC | 11.1K +11.1K (+100.0%) | 43.7K +43.7K (+100.0%) | 0.02% +0.019 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 8 qtrs — |
| 81 | JAIN GLOBAL LLC | 10.7K -17.4K (-62.0%) | 41.9K -89.3K (-68.1%) | 0.02% -0.030 pp | 0.00% 0.000 pp | USD3.59 +9.5% | 3 qtrs — |
| 82 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 9.6K -120.0 (-1.2%) | 37.7K -7.7K (-16.9%) | 0.02% 0.000 pp | 0.00% -0.001 pp | USD7.79 -49.6% | 9 qtrs — |
| 83 | PINNACLE WEALTH PLANNING SERVICES, INC. | 9.4K +9.4K (+100.0%) | 37.1K +37.1K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.004 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 84 | SIMPLEX TRADING, LLC | 8.1K +8.1K (+100.0%) | 32.0K +32.0K (+100.0%) | 0.01% +0.014 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
| 85 | CWM, LLC | 6.0K +5.0 (+0.1%) | 23.0K -5.0K (-17.9%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.74 +5.1% | 9 qtrs — |
| 86 | RUSSELL INVESTMENTS GROUP, LTD. | 4.1K +— (+0.0%) | 15.9K -3.0K (-15.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD3.38 +16.3% | 4 qtrs — |
| 87 | LEGAL & GENERAL GROUP PLC | 4.0K +— (+0.0%) | 15.6K -2.9K (-15.8%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD7.70 -49.0% | 11 qtrs — |
| 88 | AMERITAS INVESTMENT PARTNERS, INC. | 3.9K +— (+0.0%) | 15.4K -2.9K (-15.8%) | 0.01% +0.000 pp | 0.00% 0.000 pp | USD11.15 -64.8% | 11 qtrs — |
| 89 | BESSEMER GROUP INC | 3.5K +— (+0.0%) | 14.0K -2.0K (-12.5%) | 0.01% +0.000 pp | 0.00% +0.000 pp | USD7.71 -49.0% | 12 qtrs — |
| 90 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 2.9K -36.0 (-1.2%) | 11.3K -2.3K (-16.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD11.45 -65.7% | 11 qtrs — |
| 91 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 2.9K +720.0 (+33.6%) | 11.3K +1.2K (+12.4%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD6.11 -35.7% | 11 qtrs — |
| 92 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.7K -7.4K (-72.9%) | 10.8K -36.4K (-77.2%) | 0.00% -0.013 pp | 0.00% -0.001 pp | USD5.20 -24.4% | 13 qtrs — |
| 93 | CITIGROUP INC | 2.7K -2.6K (-49.4%) | 10.6K -14.3K (-57.4%) | 0.00% -0.005 pp | 0.00% +0.000 pp | USD8.20 -52.1% | 41 qtrs — |
| 94 | STERLING CAPITAL MANAGEMENT LLC | 2.7K -529.0 (-16.5%) | 10.6K -4.5K (-29.7%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD4.68 -16.0% | 6 qtrs — |
| 95 | ADVISOR GROUP HOLDINGS, INC. | 2.1K -1.1K (-33.7%) | 8.4K -5.3K (-38.7%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD7.22 -45.6% | 17 qtrs — |
| 96 | GROUP ONE TRADING, L.P. | 2.1K +2.1K (+100.0%) | 8.2K +8.2K (+100.0%) | 0.00% +0.004 pp | 0.00% +0.000 pp | USD3.93 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 59 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Invesco NASDAQ Future Gen 200 ETF QQQS | 0.44% | 97.5K | 0.20% |
| 2 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.09% | 242.5K | 0.39% |
| 3 | Innovator U.S. Small Cap Managed Floor ETF RFLR | 0.06% | 55.0K | 0.89% |
| 4 | iShares Micro-Cap ETF IWC | 0.04% | 607.6K | 0.60% |
| 5 | Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF GSSC | 0.03% | 296.7K | 0.20% |
| 6 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.02% | 11.7K | 0.35% |
| 7 | iShares Nasdaq US Biotechnology UCITS ETF BTEC.L | 0.02% | 175.3K | 0.35% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.01% | 66.4K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.01% | 10.7K | 0.19% |
| 10 | Avantis U.S. Small Cap Equity ETF AVSC | 0.01% | 412.9K | 0.25% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
1
Sells
1
Shares acquired
50.0K
Shares disposed
11.5K
Cash buys
—
Cash sales
1.00
Net activity
+38,489
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-02 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 11,511 | 3.87 | 44.5K | 472,549 | D | ↗ |
| 2026-04-01 | Shiferman Gregory L. | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 50,000 | D | ↗ |
| 2026-02-24 | Swartz Robin | Officer | S-Sale | D | Common Stock | 6,458 | 3.77 | 24.3K | 199,738 | D | ↗ |
| 2026-02-24 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 14,197 | 3.79 | 53.8K | 484,060 | D | ↗ |
| 2026-02-24 | Jorgensen Nathan D. | Officer | S-Sale | D | Common Stock | 4,668 | 3.77 | 17.6K | 151,416 | D | ↗ |
| 2026-02-24 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 4,174 | 3.76 | 15.7K | 145,718 | D | ↗ |
| 2026-02-18 | Swartz Robin | Officer | S-Sale | D | Common Stock | 3,882 | 3.44 | 13.4K | 206,196 | D | ↗ |
| 2026-02-18 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 11,732 | 3.41 | 40.0K | 498,257 | D | ↗ |
| 2026-02-18 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 3,301 | 3.44 | 11.4K | 149,892 | D | ↗ |
| 2026-02-10 | Swartz Robin | Officer | S-Sale | D | Common Stock | 4,569 | 3.85 | 17.6K | 210,078 | D | ↗ |
| 2026-02-10 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 12,192 | 3.78 | 46.1K | 509,989 | D | ↗ |
| 2026-02-10 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 3,525 | 3.85 | 13.6K | 153,193 | D | ↗ |
| 2026-02-06 | Swartz Robin | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 214,647 | D | ↗ |
| 2026-02-06 | Sandrock Alfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 402,500 | 3.68 | 1.48M | 402,500 | D | ↗ |
| 2026-02-06 | Jorgensen Nathan D. | Officer | A-Award | A | Common Stock | 32,250 | 0.00 | — | 156,084 | D | ↗ |
| 2026-02-06 | Ferguson Toby | Officer | A-Award | A | Common Stock | 45,000 | 0.00 | — | 183,914 | D | ↗ |
| 2026-02-06 | Carter Todd Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 154,000 | 3.68 | 566.7K | 154,000 | D | ↗ |
| 2026-01-06 | Shiferman Gregory L. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 4.02 | 402.0K | 100,000 | D | ↗ |
| 2025-10-03 | Jorgensen Nathan D. | Officer | S-Sale | D | Common Stock | 7,666 | 4.78 | 36.6K | 123,834 | D | ↗ |
| 2025-08-18 | Ferguson Toby | Officer | S-Sale | D | Common Stock | 19,000 | 3.73 | 70.9K | 138,914 | D | ↗ |
| 2025-06-03 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | SCANGOS GEORGE A | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | Onyia Jude | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-06-03 | Colon Grace | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 3.28 | 78.7K | 24,000 | D | ↗ |
| 2025-04-02 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 10,885 | 3.43 | 37.3K | 430,931 | D | ↗ |
| 2025-04-02 | Ferguson Toby | Officer | S-Sale | D | Common Stock | 10,086 | 3.43 | 34.6K | 157,914 | D | ↗ |
| 2025-02-21 | Swartz Robin | Officer | A-Award | A | Common Stock | 71,250 | 0.00 | — | 169,647 | D | ↗ |
| 2025-02-21 | Sandrock Alfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 290,000 | 4.22 | 1.22M | 290,000 | D | ↗ |
| 2025-02-21 | Jorgensen Nathan D. | Officer | A-Award | A | Stock Option (Right to Buy) | 103,000 | 4.22 | 434.7K | 103,000 | D | ↗ |
| 2025-02-21 | Ferguson Toby | Officer | A-Award | A | Common Stock | 63,000 | 0.00 | — | 168,000 | D | ↗ |
| 2025-02-21 | Fahey Sandell Jacquelyn | Officer | A-Award | A | Stock Option (Right to Buy) | 83,000 | 4.22 | 350.3K | 83,000 | D | ↗ |
| 2025-02-21 | Carter Todd Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 92,000 | 4.22 | 388.2K | 92,000 | D | ↗ |
| 2025-02-20 | Swartz Robin | Officer | S-Sale | D | Common Stock | 3,894 | 4.25 | 16.5K | 98,397 | D | ↗ |
| 2025-02-20 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 11,702 | 4.24 | 49.6K | 296,816 | D | ↗ |
| 2025-02-20 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 3,305 | 4.26 | 14.1K | 77,718 | D | ↗ |
| 2025-02-11 | Swartz Robin | Officer | S-Sale | D | Common Stock | 6,950 | 4.45 | 30.9K | 102,291 | D | ↗ |
| 2025-02-11 | Sandrock Alfred | Officer | S-Sale | D | Common Stock | 16,644 | 4.45 | 74.1K | 308,518 | D | ↗ |
| 2025-02-11 | Fahey Sandell Jacquelyn | Officer | S-Sale | D | Common Stock | 4,358 | 4.45 | 19.4K | 81,643 | D | ↗ |
| 2025-02-11 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 5,413 | 4.45 | 24.1K | 81,023 | D | ↗ |
| 2025-01-14 | Swartz Robin | Officer | S-Sale | D | Common Stock | 3,087 | 5.09 | 15.7K | 109,241 | D | ↗ |
| 2025-01-14 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 1,191 | 5.13 | 6.1K | 86,436 | D | ↗ |
| 2024-12-23 | Swartz Robin | Officer | S-Sale | D | Common Stock | 6,500 | 5.65 | 36.7K | 112,328 | D | ↗ |
| 2024-10-02 | Fahey Sandell Jacquelyn | Officer | S-Sale | D | Common Stock | 5,999 | 5.82 | 34.9K | 86,001 | D | ↗ |
| 2024-10-01 | Jorgensen Nathan D. | Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 80,000 | D | ↗ |
| 2024-07-08 | Jorgensen Nathan D. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-06-05 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | SCANGOS GEORGE A | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | Onyia Jude | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-06-05 | Colon Grace | Director | A-Award | A | Stock Option (Right to Buy) | 24,000 | 8.70 | 208.8K | 24,000 | — | ↗ |
| 2024-04-02 | Swartz Robin | Officer | S-Sale | D | Common Stock | 1,357 | 9.88 | 13.4K | 117,004 | — | ↗ |
| 2024-04-02 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 12,115 | 9.86 | 119.5K | 322,839 | — | ↗ |
| 2024-04-01 | Ferguson Toby | Officer | A-Award | A | Common Stock | 105,000 | 0.00 | — | 105,000 | — | ↗ |
| 2024-03-25 | Ferguson Toby | Officer | A-Award | A | Stock Option (Right to Buy) | 210,000 | 9.26 | 1.94M | 210,000 | — | ↗ |
| 2024-02-21 | Swartz Robin | Officer | S-Sale | D | Common Stock | 3,966 | 7.45 | 29.5K | 118,361 | — | ↗ |
| 2024-02-21 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 13,033 | 7.46 | 97.2K | 334,954 | — | ↗ |
| 2024-02-21 | PFREUNDSCHUH PETER P. | Officer | S-Sale | D | Common Stock | 3,764 | 7.46 | 28.1K | 175,669 | — | ↗ |
| 2024-02-21 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 3,365 | 7.47 | 25.1K | 87,627 | — | ↗ |
| 2024-02-20 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 602 | 7.68 | 4.6K | 90,992 | — | ↗ |
| 2024-02-09 | Swartz Robin | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 7.60 | 760.0K | 100,000 | — | ↗ |
| 2024-02-09 | Sandrock Alfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 260,000 | 7.60 | 1.98M | 260,000 | — | ↗ |
| 2024-02-09 | PFREUNDSCHUH PETER P. | Officer | A-Award | A | Stock Option (Right to Buy) | 60,000 | 7.60 | 456.0K | 60,000 | — | ↗ |
| 2024-02-09 | Fahey Sandell Jacquelyn | Officer | A-Award | A | Stock Option (Right to Buy) | 62,000 | 7.60 | 471.2K | 62,000 | — | ↗ |
| 2024-02-09 | Carter Todd Alfred | Officer | A-Award | A | Stock Option (Right to Buy) | 77,000 | 7.60 | 585.2K | 77,000 | — | ↗ |
| 2024-01-17 | Swartz Robin | Officer | S-Sale | D | Common Stock | 2,543 | 7.15 | 18.2K | 72,327 | — | ↗ |
| 2024-01-17 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 1,266 | 7.18 | 9.1K | 53,094 | — | ↗ |
| 2023-10-03 | PFREUNDSCHUH PETER P. | Officer | S-Sale | D | Common Stock | 13,567 | 6.99 | 94.8K | 149,433 | — | ↗ |
| 2023-10-01 | Fahey Sandell Jacquelyn | Officer | A-Award | A | Common Stock | 61,000 | 0.00 | — | 61,000 | — | ↗ |
| 2023-09-15 | Carter Todd Alfred | Officer | M-Exempt | D | Stock Option (Right to Buy) | 5,000 | 2.85 | 14.3K | 40,000 | — | ↗ |
| 2023-07-10 | Fahey Sandell Jacquelyn | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-06 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 5,500 | 10.80 | 59.4K | 59,860 | — | ↗ |
| 2023-06-30 | Carter Todd Alfred | Officer | M-Exempt | A | Common Stock | 5,000 | 2.85 | 14.3K | 70,360 | — | ↗ |
| 2023-06-06 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | SCANGOS GEORGE A | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | Onyia Jude | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-06-06 | Colon Grace | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 12.57 | 276.5K | 22,000 | — | ↗ |
| 2023-05-09 | SCANGOS GEORGE A | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 10.76 | 473.4K | 44,000 | — | ↗ |
| 2023-04-03 | Swartz Robin | Officer | S-Sale | D | Common Stock | 1,259 | 7.83 | 9.9K | 71,617 | — | ↗ |
| 2023-04-03 | Sandrock Alfred | Director / Officer | S-Sale | D | Common Stock | 7,437 | 7.83 | 58.2K | 214,618 | — | ↗ |
| 2023-03-15 | Swartz Robin | Officer | S-Sale | D | Common Stock | 15,373 | 8.20 | 126.1K | 76,530 | — | ↗ |
| 2023-02-23 | Onyia Jude | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.92 | 304.5K | 44,000 | — | ↗ |
| 2023-02-23 | NEUROCRINE BIOSCIENCES INC | 10% Owner | P-Purchase | A | Common Stock | 4,395,588 | 8.88 | 39.03M | 8,575,316 | — | ↗ |
| 2023-02-17 | Swartz Robin | Officer | A-Award | A | Stock Option (Right to Buy) | 80,000 | 7.43 | 594.4K | 80,000 | — | ↗ |
| 2023-02-17 | Sandrock Alfred | Director / Officer | A-Award | A | Common Stock | 120,000 | 0.00 | — | 222,055 | — | ↗ |
| 2023-02-17 | PFREUNDSCHUH PETER P. | Officer | A-Award | A | Stock Option (Right to Buy) | 76,000 | 7.43 | 564.7K | 76,000 | — | ↗ |
| 2023-02-17 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 3,297 | 7.45 | 24.6K | 106,610 | — | ↗ |
| 2023-02-17 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 738 | 7.45 | 5.5K | 67,553 | — | ↗ |
| 2023-02-13 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 2,868 | 7.67 | 22.0K | 109,907 | — | ↗ |
| 2023-02-13 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 797 | 7.67 | 6.1K | 34,291 | — | ↗ |
| 2023-02-02 | Third Rock Ventures III, L.P. | 10% Owner | J-Other | D | Common Stock | 1,500,000 | 0.00 | — | 3,185,291 | — | ↗ |
| 2023-02-01 | Third Rock Ventures III, L.P. | 10% Owner | S-Sale | D | Common Stock | 128,642 | 9.32 | 1.20M | 4,685,291 | — | ↗ |
| 2023-01-31 | Third Rock Ventures III, L.P. | 10% Owner | S-Sale | D | Common Stock | 185,000 | 9.25 | 1.71M | 4,813,933 | — | ↗ |
| 2023-01-30 | Third Rock Ventures III, L.P. | 10% Owner | S-Sale | D | Common Stock | 75,000 | 9.03 | 677.3K | 4,998,933 | — | ↗ |
| 2023-01-27 | Third Rock Ventures III, L.P. | Director | S-Sale | D | Common Stock | 50,000 | 9.02 | 451.0K | 5,073,933 | — | ↗ |
| 2023-01-25 | Third Rock Ventures III, L.P. | Director | S-Sale | D | Common Stock | 50,000 | 9.22 | 461.0K | 5,123,933 | — | ↗ |
| 2023-01-24 | Third Rock Ventures III, L.P. | Director | S-Sale | D | Common Stock | 100,000 | 9.27 | 927.0K | 5,173,933 | — | ↗ |
| 2023-01-23 | Third Rock Ventures III, L.P. | Director | S-Sale | D | Common Stock | 55,000 | 9.06 | 498.3K | 5,273,933 | — | ↗ |
| 2023-01-20 | Third Rock Ventures III, L.P. | Director | S-Sale | D | Common Stock | 100,000 | 9.15 | 915.0K | 5,328,933 | — | ↗ |
| 2023-01-17 | Swartz Robin | Officer | S-Sale | D | Common Stock | 1,396 | 9.57 | 13.4K | 52,695 | — | ↗ |
| 2023-01-17 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 1,396 | 9.57 | 13.4K | 113,567 | — | ↗ |
| 2023-01-17 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 706 | 9.57 | 6.8K | 35,488 | — | ↗ |
| 2023-01-11 | EcoR1 Capital, LLC | Director | S-Sale | D | Common Stock | 110,000 | 8.50 | 934.6K | 3,851,507 | — | ↗ |
| 2023-01-10 | EcoR1 Capital, LLC | Director | S-Sale | D | Common Stock | 336,400 | 8.05 | 2.71M | 3,961,507 | — | ↗ |
| 2023-01-09 | EcoR1 Capital, LLC | Director | S-Sale | D | Common Stock | 456,000 | 7.67 | 3.50M | 4,297,907 | — | ↗ |
| 2023-01-06 | Carter Todd Alfred | Officer | S-Sale | D | Common Stock | 388 | 6.41 | 2.5K | 36,194 | — | ↗ |
| 2023-01-01 | Colon Grace | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-12-31 | Carter Todd Alfred | Officer | A-Award | A | Common Stock | 388 | 5.17 | 2.0K | 36,582 | — | ↗ |
| 2022-10-01 | PFREUNDSCHUH PETER P. | Officer | A-Award | A | Common Stock | 125,000 | 0.00 | — | 125,000 | — | ↗ |
| 2022-08-24 | TEPPER ROBERT I | Director | S-Sale | D | Common Stock | 200,000 | 6.22 | 1.24M | 5,428,933 | — | ↗ |
| 2022-08-16 | TEPPER ROBERT I | Director | S-Sale | D | Common Stock | 128,456 | 6.04 | 775.9K | 5,778,905 | — | ↗ |
| 2022-08-15 | MACKEY CATHERINE J | Director | A-Award | A | Stock Option (Right to Buy) | 44,000 | 6.02 | 264.9K | 44,000 | — | ↗ |
| 2022-08-12 | TEPPER ROBERT I | Director | S-Sale | D | Common Stock | 135,808 | 6.04 | 820.3K | 5,907,361 | — | ↗ |
| 2022-07-14 | PIERCE GLENN | Director | S-Sale | D | Common Stock | 9,512 | 6.70 | 63.7K | 16,788 | — | ↗ |
| 2022-07-14 | Higgins Michael J | Director | S-Sale | D | Common Stock | 13,891 | 6.70 | 93.1K | 31,314 | — | ↗ |
| 2022-06-21 | EcoR1 Capital, LLC | Director | P-Purchase | A | Common Stock | 376,000 | 5.66 | 2.13M | 4,753,907 | — | ↗ |
| 2022-06-06 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-06-06 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 5.27 | 115.9K | 22,000 | — | ↗ |
| 2022-06-06 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-06-06 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-06-06 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 22,000 | 0.00 | — | 22,000 | — | ↗ |
| 2022-04-21 | EcoR1 Capital, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 4,276,507 | — | ↗ |
| 2022-04-04 | Swartz Robin | Officer | S-Sale | D | Common Stock | 1,527 | 8.25 | 12.6K | 52,060 | — | ↗ |
| 2022-04-04 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 2,786 | 8.25 | 23.0K | 114,963 | — | ↗ |
| 2022-03-22 | Sandrock Alfred | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 940,600 | 8.55 | 8.04M | 940,600 | — | ↗ |
| 2022-03-21 | Swartz Robin | Officer | S-Sale | D | Common Stock | 4,362 | 8.29 | 36.2K | 53,638 | — | ↗ |
| 2022-03-21 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 58 | 8.68 | 503.44 | 117,749 | — | ↗ |
| 2022-03-21 | Burek Julie | Officer | S-Sale | D | Common Stock | 31 | 8.68 | 269.08 | 52,458 | — | ↗ |
| 2022-02-17 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 4,100 | 3.55 | 14.6K | 122,704 | — | ↗ |
| 2022-02-17 | Burek Julie | Officer | S-Sale | D | Common Stock | 789 | 3.55 | 2.8K | 55,107 | — | ↗ |
| 2022-02-11 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 3,252 | 3.36 | 10.9K | 126,804 | — | ↗ |
| 2022-02-11 | Burek Julie | Officer | S-Sale | D | Common Stock | 361 | 3.36 | 1.2K | 55,896 | — | ↗ |
| 2022-02-07 | Swartz Robin | Officer | — | D | Common Stock | 0 | 0.00 | — | 58,000 | — | ↗ |
| 2022-02-07 | Sandrock Alfred | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-01-13 | PIERCE GLENN | Director / Officer | A-Award | A | Common Stock | 26,300 | 0.00 | — | 26,300 | — | ↗ |
| 2022-01-13 | Higgins Michael J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 161,000 | 2.85 | 458.9K | 161,000 | — | ↗ |
| 2022-01-13 | Hesslein Robert W. | Officer | A-Award | A | Stock Option (Right to Buy) | 120,000 | 2.85 | 342.0K | 120,000 | — | ↗ |
| 2022-01-13 | Burek Julie | Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 2.85 | 114.0K | 40,000 | — | ↗ |
| 2022-01-12 | Burek Julie | Officer | S-Sale | D | Common Stock | 265 | 3.06 | 810.90 | 46,257 | — | ↗ |
| 2022-01-03 | Burek Julie | Officer | S-Sale | D | Common Stock | 3,063 | 2.83 | 8.7K | 46,522 | — | ↗ |
| 2021-12-31 | Burek Julie | Officer | A-Award | A | Common Stock | 3,063 | 2.30 | 7.0K | 49,585 | — | ↗ |
| 2021-11-26 | Burek Julie | Officer | A-Award | A | Common Stock | 13,500 | 0.00 | — | 46,522 | — | ↗ |
| 2021-06-07 | PIERCE GLENN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 42,000 | 4.45 | 186.9K | 42,000 | — | ↗ |
| 2021-06-03 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.23 | 63.5K | 15,000 | — | ↗ |
| 2021-06-03 | PIERCE GLENN | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 4.23 | 211.5K | 50,000 | — | ↗ |
| 2021-06-03 | PAUL STEVEN M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.23 | 63.5K | 15,000 | — | ↗ |
| 2021-06-03 | LEVIN MARK J | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.23 | 63.5K | 15,000 | — | ↗ |
| 2021-06-03 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.23 | 63.5K | 15,000 | — | ↗ |
| 2021-06-03 | Higgins Michael J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 115,000 | 4.23 | 486.5K | 115,000 | — | ↗ |
| 2021-06-03 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 4.23 | 63.5K | 15,000 | — | ↗ |
| 2021-05-21 | Khwaja Omar | Officer | S-Sale | D | Common Stock | 3,516 | 4.03 | 14.2K | 120,509 | — | ↗ |
| 2021-04-05 | Hesslein Robert W. | Officer | S-Sale | A | Common Stock | 3,292 | 4.95 | 16.3K | 110,056 | — | ↗ |
| 2021-03-19 | Turenne Andre | Director / Officer | A-Award | A | Common Stock | 80,000 | 0.00 | — | 322,375 | — | ↗ |
| 2021-03-19 | Khwaja Omar | Officer | A-Award | A | Common Stock | 35,000 | 0.00 | — | 124,025 | — | ↗ |
| 2021-03-19 | Hesslein Robert W. | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 113,348 | — | ↗ |
| 2021-03-19 | Dorval Allison | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 109,894 | — | ↗ |
| 2021-02-16 | Turenne Andre | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 189,000 | 7.33 | 1.39M | 189,000 | — | ↗ |
| 2021-02-16 | Khwaja Omar | Officer | A-Award | A | Stock Option (Right to Buy) | 72,000 | 7.33 | 527.8K | 72,000 | — | ↗ |
| 2021-02-16 | Hesslein Robert W. | Officer | A-Award | A | Common Stock | 34,000 | 0.00 | — | 83,348 | — | ↗ |
| 2021-02-16 | Dorval Allison | Officer | A-Award | A | Stock Option (Right to Buy) | 68,000 | 7.33 | 498.4K | 68,000 | — | ↗ |
| 2021-02-11 | Turenne Andre | Director / Officer | S-Sale | D | Common Stock | 7,977 | 7.55 | 60.2K | 148,375 | — | ↗ |
| 2021-02-11 | Khwaja Omar | Officer | S-Sale | D | Common Stock | 3,475 | 7.55 | 26.2K | 53,025 | — | ↗ |
| 2021-02-11 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 3,186 | 7.55 | 24.1K | 49,348 | — | ↗ |
| 2021-02-11 | Dorval Allison | Officer | S-Sale | D | Common Stock | 3,186 | 7.55 | 24.1K | 45,894 | — | ↗ |
| 2021-01-12 | Turenne Andre | Director / Officer | S-Sale | D | Common Stock | 10,443 | 8.62 | 90.0K | 156,352 | — | ↗ |
| 2021-01-12 | Dorval Allison | Officer | S-Sale | D | Common Stock | 2,942 | 8.62 | 25.4K | 49,080 | — | ↗ |
| 2020-09-15 | Vitale Nancy | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 10.85 | 325.5K | 30,000 | — | ↗ |
| 2020-06-04 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | PAUL STEVEN M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | LEVIN MARK J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | Hyman Steven | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | Higgins Michael J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | GERAGHTY JAMES A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-06-04 | DIXON WENDY L | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 11.79 | 176.9K | 15,000 | — | ↗ |
| 2020-05-21 | Khwaja Omar | Officer | S-Sale | D | Common Stock | 3,500 | 12.96 | 45.4K | 56,500 | — | ↗ |
| 2020-04-03 | Hesslein Robert W. | Officer | S-Sale | D | Common Stock | 3,091 | 8.51 | 26.3K | 52,534 | — | ↗ |
| 2020-02-10 | Turenne Andre | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 162,500 | 12.96 | 2.11M | 162,500 | — | ↗ |
| 2020-02-10 | Khwaja Omar | Officer | A-Award | A | Common Stock | 30,000 | 0.00 | — | 60,000 | — | ↗ |
| 2020-02-10 | Hesslein Robert W. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 12.96 | 712.8K | 55,000 | — | ↗ |
| 2020-02-10 | Dorval Allison | Officer | A-Award | A | Common Stock | 27,500 | 0.00 | — | 52,022 | — | ↗ |
| 2020-01-21 | Turenne Andre | Director / Officer | S-Sale | D | Common Stock | 10,705 | 13.36 | 143.0K | 85,545 | — | ↗ |
| 2020-01-21 | Ottmer Matthew P. | Officer | S-Sale | D | Common Stock | 3,724 | 13.36 | 49.8K | 26,276 | — | ↗ |
| 2020-01-21 | Dorval Allison | Officer | S-Sale | D | Common Stock | 3,128 | 13.36 | 41.8K | 24,522 | — | ↗ |
| 2019-06-13 | PIERCE GLENN | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 24.68 | 370.2K | 15,000 | — | ↗ |
| 2019-06-13 | PAUL STEVEN M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 24.68 | 370.2K | 15,000 | — | ↗ |
| 2019-06-13 | LEVIN MARK J | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 24.68 | 370.2K | 15,000 | — | ↗ |
| 2019-06-13 | KARSEN PERRY A | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 24.68 | 370.2K | 15,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.7K
Shares Outstanding
60.42M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 674.9K | — | 611.9K | 843.9K | 361.9K | 15.8K | 2.51M | 58.04% | ↗ |
| 2 | 2025 | Jacquelyn Fahey Sandell Former Chief Legal Officer | 297.8K | — | 175.1K | 241.5K | — | 760.5K | 1.47M | 28.25% | ↗ |
| 3 | 2025 | Robin Swartz Chief Business Officer & Chief Operating Officer | 520.2K | — | 300.7K | 414.7K | 205.5K | 13.3K | 1.45M | 49.19% | ↗ |
| 4 | 2025 | Toby Ferguson, M.D., Ph.D. Former Chief Medical Officer | 513.4K | — | 265.9K | 366.7K | 202.8K | 15.8K | 1.36M | 46.36% | ↗ |
| 5 | 2024 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 652.1K | — | 988.0K | 1.37M | 351.5K | 15.5K | 3.38M | 69.85% | ↗ |
| 6 | 2024 | Toby Ferguson, M.D., Ph.D. Chief Medical Officer | 367.8K | — | 1.11M | 1.33M | 148.2K | 13.1K | 2.97M | 82.18% | ↗ |
| 7 | 2024 | Toby Ferguson, M.D., Ph.D. Former Chief Medical Officer | 363.8K | — | 1.11M | 1.33M | 148.2K | 14.7K | 2.97M | 82.25% | ↗ |
| 8 | 2024 | Nathan Jorgensen, Ph D. Chief Financial Officer | 228.0K | — | 468.0K | 1.07M | 90.9K | 13.1K | 1.87M | 82.25% | ↗ |
| 9 | 2024 | Robin Swartz Chief Business Officer & Chief Operating Officer | 490.7K | — | 380.0K | 528.0K | 199.5K | 15.5K | 1.61M | 56.26% | ↗ |
| 10 | 2024 | Jacquelyn Fahey Sandell Former Chief Legal Officer | 468.8K | — | 235.6K | 327.4K | 185.1K | 15.5K | 1.23M | 45.68% | ↗ |
| 11 | 2023 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 624.0K | — | 891.6K | 1.27M | 377.5K | 13.1K | 3.17M | 68.02% | ↗ |
| 12 | 2023 | Jacquelyn Fahey Sandell Chief Legal Officer | 207.7K | — | 472.8K | 895.9K | 94.0K | 7.0K | 1.68M | 81.60% | ↗ |
| 13 | 2023 | Robin Swartz Chief Operating Officer | 449.4K | — | 297.2K | 422.1K | 199.5K | 13.1K | 1.38M | 52.07% | ↗ |
| 14 | 2022 | Alfred Sandrock, M.D., Ph.D. Chief Executive Officer, President, and Director | 525.4K | 50.0K | 855.0K | 5.72M | 250.0K | 10.4K | 7.41M | 88.72% | ↗ |
| 15 | 2022 | Peter P. Pfreundschuh Chief Financial Officer | 122.5K | — | 740.0K | 879.2K | 50.2K | — | 1.79M | 90.36% | ↗ |
| 16 | 2022 | Robert W. Hesslein Senior Vice President and General Counsel | 450.8K | — | 57.0K | 231.4K | 175.4K | — | 914.6K | 31.53% | ↗ |
| 17 | 2022 | Michael Higgins Former Interim President and Chief Executive Officer | 235.7K | — | 128.8K | 393.0K | — | — | 757.5K | 68.88% | ↗ |
| 18 | 2021 | G. Andre Turenne Former President and Chief Executive Officer | 600.3K | — | 1.13M | 897.6K | — | — | 2.63M | 77.18% | ↗ |
| 19 | 2021 | Robert W. Hesslein Senior Vice President and General Counsel | 430.0K | — | 415.4K | 322.9K | 141.1K | — | 1.31M | 56.39% | ↗ |
| 20 | 2021 | Allison Dorval Former Chief Financial Officer | 393.2K | — | 415.4K | 322.9K | — | — | 1.13M | 65.25% | ↗ |
| 21 | 2021 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 196.8K | — | 457.8K | 341.9K | — | — | 996.5K | 80.25% | ↗ |
| 22 | 2021 | Michael Higgins Former Interim President and Chief Executive Officer | 379.2K | — | — | 316.9K | — | — | 696.1K | 45.53% | ↗ |
| 23 | 2021 | Glenn Pierce, M.D., Ph.D. Interim Chief Scientific Officer | 293.3K | — | — | 259.4K | — | — | 552.7K | 46.94% | ↗ |
| 24 | 2020 | G. Andre Turenne Former President and Chief Executive Officer | 580.0K | — | 1.05M | 1.35M | 293.5K | — | 3.27M | 73.32% | ↗ |
| 25 | 2020 | G. Andre Turenne President and Chief Executive Officer | 580.0K | — | — | — | 293.5K | — | 3.27M | 0.00% | ↗ |
| 26 | 2020 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 449.5K | — | — | — | 165.4K | 144.1K | 1.65M | 0.00% | ↗ |
| 27 | 2020 | Omar Khwaja, M.D., Ph.D. Former Chief Medical Officer and Head of Research and Development | 449.5K | — | 388.8K | 497.6K | 165.4K | 144.1K | 1.65M | 53.87% | ↗ |
| 28 | 2020 | Robert W. Hesslein Senior Vice President and General Counsel | 420.8K | — | 356.4K | 456.1K | 157.0K | 2.8K | 1.39M | 58.32% | ↗ |
| 29 | 2020 | Allison Dorval Former Chief Financial Officer | 403.1K | — | 356.4K | 456.1K | 150.4K | 550.00 | 1.37M | 59.45% | ↗ |
| 30 | 2019 | Omar Khwaja, M.D., Ph.D. Chief Medical Officer and Head of Research and Development | 271.2K | 100.0K | — | — | 167.2K | 160.2K | 3.82M | 0.00% | ↗ |
| 31 | 2019 | Robert W. Hesslein Senior Vice President and General Counsel | 307.5K | — | — | — | 134.5K | — | 3.24M | 0.00% | ↗ |
| 32 | 2019 | G. Andre Turenne President and Chief Executive Officer | 540.8K | — | — | — | 256.9K | — | 2.84M | 0.00% | ↗ |
| 33 | 2018 | G. Andre Turenne President and Chief Executive Officer | 240.0K | — | — | — | 143.3K | — | 8.21M | 0.00% | ↗ |
| 34 | 2018 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 298.3K | — | — | 7.47M | — | 106.5K | 7.88M | 94.86% | ↗ |
| 35 | 2018 | Matthew P. Ottmer Chief Operating Officer | 411.3K | — | — | 1.25M | 191.3K | — | 1.85M | 67.40% | ↗ |
| 36 | 2018 | Dinah Sah, Ph.D. Chief Scientific Officer | 381.3K | — | — | 1.25M | 182.6K | — | 1.81M | 68.84% | ↗ |
| 37 | 2017 | Matthew P. Ottmer Chief Operating Officer | 124.4K | — | — | 2.57M | 132.3K | — | 2.83M | 90.93% | ↗ |
| 38 | 2017 | Steven M. Paul, M.D. President and Chief Executive Officer | 506.9K | — | — | 1.86M | 239.5K | 48.3K | 2.66M | 70.07% | ↗ |
| 39 | 2017 | Steven M. Paul, M.D. Former President and Chief Executive Officer | 506.9K | — | — | 1.86M | 239.5K | 48.3K | 2.66M | 70.07% | ↗ |
| 40 | 2017 | Jane Pritchett Henderson Chief Financial Officer and Senior Vice President of Corporate Development | 370.0K | — | — | 1.68M | 119.3K | 80.4K | 2.25M | 74.64% | ↗ |
| 41 | 2017 | Dinah Sah, Ph.D. Chief Scientific Officer | 363.8K | — | — | 503.9K | 120.3K | — | 988.1K | 51.00% | ↗ |
| 42 | 2016 | Steven M. Paul, M.D. President and Chief Executive Officer | 485.1K | — | — | 2.69M | 242.6K | 18.3K | 3.44M | 78.29% | ↗ |
| 43 | 2016 | Dinah Sah, Ph.D. Chief Scientific Officer | 330.8K | — | — | 712.4K | 99.2K | — | 1.14M | 62.36% | ↗ |
| 44 | 2016 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 343.1K | — | — | 428.3K | 102.9K | 50.0K | 924.3K | 46.33% | ↗ |
| 45 | 2015 | Steven M. Paul, M.D. President and Chief Executive Officer | 450.0K | — | — | 400.9K | 203.4K | 18.6K | 1.07M | 37.37% | ↗ |
| 46 | 2015 | Steven M. Paul, M.D. President & Chief Executive Officer | 450.0K | — | — | 400.9K | 203.4K | 18.6K | 1.07M | 37.37% | ↗ |
| 47 | 2015 | Dinah Sah, Ph.D. Chief Scientific Officer | 315.0K | — | — | 426.2K | 78.8K | — | 819.9K | 51.98% | ↗ |
| 48 | 2015 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 336.4K | — | — | 88.9K | 76.0K | 50.0K | 551.3K | 16.12% | ↗ |
| 49 | 2015 | Bernard Ravina, M.D. Vice President, Clinical Development | 309.0K | 35.0K | — | 88.5K | 77.3K | — | 474.8K | 18.64% | ↗ |
| 50 | 2014 | Steven M. Paul, M.D. President & Chief Executive Officer | 150.0K | — | — | 877.0K | — | 5.9K | 1.03M | 84.91% | ↗ |
| 51 | 2014 | Bernard Ravina, M.D. Vice President, Clinical Development | 231.7K | 66.1K | — | 55.0K | — | — | 387.8K | 14.18% | ↗ |
| 52 | 2014 | Robert Pietrusko, Pharm.D. Senior Vice President, Regulatory Affairs and Quality Assurance | 174.8K | 1.2K | — | 125.0K | — | 50.0K | 351.0K | 35.62% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Alfred W. Sandrock Jr. | President, Chief Executive Officer & Director | 1M | — |
| Robin Swartz | Chief Business Officer & Chief Operating Officer | 739.0K | female |
| Nathan D. Jorgensen | Chief Financial Officer | 577.7K | — |
| Mark A. Kay | Founder | — | — |
| Mathieu Nonnenmacher | Vice President of Gene Therapy | — | — |
| Todd Carter | Chief Scientific Officer | — | male |
| Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | — | female |
| Gregory Shiferman | Senior VP, General Counsel & Secretary | — | male |
| Krystof Bankiewicz | Founder | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VYGR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
